Jaume Capdevila-Castillon - Publications

SEOM-GETNE clinical guidelines for the diagnosis and treatment of gastroenteropancreatic and bronchial neuroendocrine neoplasms (NENs) (2022).

Journal: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico

Published: April 18, 2023

Correction to: SEOM‑GEMCAD‑TTD clinical guidelines for localized rectal cancer (2021).

Journal: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico

Published: May 20, 2022

SEOM-GEMCAD-TTD clinical guidelines for localized rectal cancer (2021).

Journal: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico

Published: February 22, 2022

Identification of Expression Profiles Defining Distinct Prognostic Subsets of Radioactive-Iodine Refractory Differentiated Thyroid Cancer from the DECISION Trial.

Journal: Molecular cancer therapeutics

Published: March 04, 2019

Meta-Analysis of Randomized Clinical Trials Comparing Active Treatment with Placebo in Metastatic Neuroendocrine Tumors.

Journal: The oncologist

Published: October 09, 2018

Consensus document on the progression and treatment response criteria in gastroenteropancreatic neuroendocrine tumors.

Journal: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico

Published: January 09, 2018

Optimisation of treatment with lenvatinib in radioactive iodine-refractory differentiated thyroid cancer.

Journal: Cancer treatment reviews

Published: December 18, 2017

Phase II Study of Everolimus and Octreotide LAR in Patients with Nonfunctioning Gastrointestinal Neuroendocrine Tumors: The GETNE1003_EVERLAR Study.

Journal: The oncologist

Published: November 28, 2017

Consensus on the management of advanced radioactive iodine-refractory differentiated thyroid cancer on behalf of the Spanish Society of Endocrinology Thyroid Cancer Working Group (GTSEEN) and Spanish Rare Cancer Working Group (GETHI).

Journal: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico

Published: July 26, 2016

Evaluation of the efficacy and safety of lanreotide in combination with targeted therapies in patients with neuroendocrine tumours in clinical practice: a retrospective cross-sectional analysis.

Journal: BMC cancer

Published: May 04, 2014

A randomized phase II study of capecitabine-based chemoradiation with or without bevacizumab in resectable locally advanced rectal cancer: clinical and biological features.

Journal: BMC cancer

Published: April 07, 2014

What could Nintedanib (BIBF 1120), a triple inhibitor of VEGFR, PDGFR, and FGFR, add to the current treatment options for patients with metastatic colorectal cancer?

Journal: Critical reviews in oncology/hematology

Published: February 17, 2014